



Supplementary Figure 1. PubMed search



Supplementary Figure 1. ("study protocol*" OR "research protocol*" OR "trial protocol*") AND (((neoplasms [MeSH Terms] OR cancer* [TW] OR neoplas*[TW] OR carcinoma*[TW] OR maligna*[TW] OR tumor*[TW] OR tumour*[TW] OR oncolog*[TI]) AND ((head OR neck OR mouth OR "oral cavity" OR pharynx OR pharyngeal* OR larynx OR nose OR nasal OR paranasal OR salivary OR uadt OR "upper aerodigestive" OR "upper aero-digestive" OR gingival OR otorhinolar* OR "oto rhino laryng*" OR "otorhino laryng*" OR tongue OR tonsil* or palatal))) OR ("Head and Neck Neoplasms"[Mesh]))


Article (Books and documents, clinical trial, Randomized Controlled Trial, with full text available)

Supplementary Figure 2. Embase search




Supplementary Figure 2. ('study protocol*' OR 'research protocol*' OR 'trial protocol*') AND ('head and neck tumor'/exp OR 'head and neck tumor' OR ((cancer*:ti OR neoplas*:ti OR carcinoma:ti OR maligna*:ti OR tumor:ti OR tumour* OR oncolog*:ti) AND ('head' OR 'head'/exp OR head OR 'neck' OR 'neck'/exp OR neck OR 'mouth' OR 'mouth'/exp OR mouth OR 'oral cavity'/exp OR 'oral cavity' OR 'pharynx' OR 'pharynx'/exp OR pharynx OR pharyngeal* OR 'larynx' OR 'larynx'/exp OR larynx OR 'nose' OR 'nose'/exp OR nose OR nasal OR paranasal OR salivary OR uadt OR 'upper aerodigestive' OR 'upper aero-digestive' OR gingival OR otorhinolar* OR 'oto rhino laryng*' OR 'otorhino laryng*' OR 'tongue' OR 'tongue'/exp OR tongue OR tonsil* OR palatal)) OR 'upper aerodigestive tract cancer'/exp OR 'upper aerodigestive tract cancer') AND [embase]/lim NOT ([embase]/lim AND [medline]/lim) AND ('article'/it OR 'review'/it)

Supplementary Figure 3




Supplementary Figure 3. Graphical representation of the Odds Ratios (OR) and confidence interval relative to the S/G mention in the overall sample. The estimated OR is represented by the dot, while lines represent the 95%CI. The 95%CI fully to the left/right of the vertical axis, correspondent to OR=1, means a significant lower/higher S/G mention in the category of interest.

Supplementary Figure 4



Supplementary Figure 4. Graphical representation of the Odds Ratios (OR) and confidence interval relative to the S/G mention by randomization. The estimated OR is represented by the dot, while lines represent the 95%CI. The 95%CI fully to the left/right of the vertical axis, correspondent to OR=1, means a significant lower/higher S/G mention in the category of interest.

Supplementary Figure 5



Supplementary Figure 5. Graphical representation of the Odds Ratios and confidence interval relative to the S/G mention of the protocols analyzed and of the published studies. The estimated OR is represented by the dot, while lines represent the 95%CI. The 95%CI fully to the left/right of the vertical axis, correspondent to OR=1, means a significant lower/higher S/G mention in the category of interest.

Supplementary Table 1

Supplementary Table 1/a. Sex/Gender mention in ClinicalTrial.gov by study characteristics			
Characteristic	S/G mentioned¹ N=1,032²	S/G NO mention¹ N=640²	P-value³
Mention in ClinicalTrial.gov(extended)			-
S/G mentioned ¹	89	-	
only eligibility	943	-	
no mention	-	640	
Study type			<0.001
Interventional	960 (68)	447 (32)	
Observational/Patient Registry	72 (27)	193 (73)	
Overall status			<0.001
Active, not recruiting	125 (72)	49 (28)	
Completed	415 (57)	309 (43)	
Recruiting/enrolling by invitation	265 (67)	132 (33)	
Not yet recruiting	73 (68)	34 (32)	
Unknown status/Suspended	154 (57)	116 (43)	
Enrolment			0.037
≤100 ⁴	750 (63,5)	431 (36,5)	
>100	282 (57)	209 (43)	
HPV mention			0.025
No Mention	840 (61)	548 (39)	
Mention	192 (68)	92 (32)	
Studies with a relevant HPV role			0.084
Other	667 (60)	440 (40)	
Oral cavity, oropharynx and larynx subsites	365 (65)	200 (35)	
Phase			<0.001
Early Phase 1/Phase1	149 (82)	33 (18)	
Phase 1/Phase 2	73 (72)	28 (28)	
Phase 2/Phase 3	606 (74)	214 (26)	
Phase 4	12 (71)	5 (29)	
Not Applicable ⁴	192 (35)	356(65)	
Randomized			0.7
No	696 (61)	438 (39)	
Yes	336 (62)	202 (38)	
¹ Sex/gender mentioned in the analysis or as eligibility criteria, ² n (%), ³ Pearson's Chi-squared test,			
⁴ missing values included			

Supplementary Table 1/b. Sex/Gender mention in controlled studies and uncontrolled studies, Odds ratio of any Sex/Gender mention vs no Sex/Gender mention												
	Controlled studies					Uncontrolled studies					Controlled vs uncontrolled	
Characteristic	Overall N=1,212 ¹ (col %)	S/G mentioned ² N=843 ¹	S/G No mention ² N=369 ¹	OR	P-value ³ CI ⁴	Overall N=204 (col %)	S/G mentioned ² N=20 ¹	S/G No mention ² N=184 ¹	OR	P-value ³ CI ⁴	OR	P-value ³ CI ⁴
Sex and gender mention, (n%)					-					-		<0.000
Analytical variable		58(5)	-				20(10)	-				ref
Recruitment only		785(65)	-				43(21)	-			6.29	3.47- 11.39
No mention		-	369 (30)				-	141(69)			0.90	0.52- 1.55
Study type (n%)					-					0.016		-
Interventional	1,212	843 (70)	369 (30)			52 (25)	23 (44)	29 (56)	2.22	1.15- 4.27		
Observational/ Patient Registry						152 (75)	40 (26)	112 (74)		ref		
Overall status (n%)					0.003					0.95		0.07
Active, not recruiting	149 (12)	116 (78)	33 (22)		ref	21 (10)	7(33)	14 (67)		ref		ref
Completed	481 (40)	310 (64)	171 (36)	0.51	0.33- 0.79	81 (40)	25 (31)	56 (69)	0.89	0.32- 2.48	0.83	0.50- 1.39
Not yet recruiting	95 (8)	70 (74)	25 (26)	0.79	0.43- 1.44	9 (4)	3 (33)	6 (67)	1	0.19- 5.24	1.48	0.65- 3.38
Recruiting/Enrolling by invitation	318 (26)	236 (74)	82 (26)	0.81	0.51- 1.29	51 (25)	17 (33)	34 (67)	1	0.34- 2.93	0.87	0.50- 1.51
Unknown status/Suspended	169 (14)	111 (66)	58 (34)	0.54	0.33- 0.89	42 (21)	11 (26)	31 (74)	0.70	0.22- 2.21	0.56	0.32- 1.00
Enrolment (n%)					0.372					0.012		<0.000
≤100 ⁵	879 (73)	605 (69)	274 (31)	0.88	0.66- 1.16	115 (56)	44 (38)	73 (62)	2.21	1.18- 4.17	2.0	1.47- 2.71
>100	333 (27)	238 (71)	95 (29)		ref	88 (43)	8 (9.1)	69 (78)		ref		ref
HPV mention (n%)	222 (18)	13 (5.9)	49 (22)	1.68	0.003	43 (21)	11 (26)	32 (74)	0.72	0.397	0.83	0.349

	1.19-2.37					0.33-1.54						0.58-1.21
Phase (n%)	<0.000					0.012						<0.000
Early Phase 1/Phase1	159 (13)	131 (82)	28 (18)		ref	4 (2)	3 (75)	1 (25)		ref		ref
Phase 1/Phase 2	85 (7)	65 (76)	20 (24)	0.16	0.10-0.26	2 (1)	1 (50)	1 (50)	0.33	0.00-11.93	1.06	0.19-5.95
Phase 2/Phase 3	717 (59)	533 (74)	184 (26)	0.69	0.36-1.32	15 (7)	9 (60)	6 (40)	0.50	0.04-6.01	1.20	0.39-3.67
Phase 4	16 (1)	12 (75)	4 (25)	0.61	0.39-0.96		-	-		-		-
Not Applicable ⁵	235 (19)	102(43)	133 (57)	0.16	0.10-0.26	183 (90)	50 (27)	133 (73)	0.12	0.01-1.23	0.03	0.01-0.08
¹ n (%), ² sex/gender mentioned in the analysis or as eligibility criteria, ³ Pearson's Chi-squared test, ⁴ OR with respect to referred category, ⁵ missing values included CI: confidence interval; OR: odds ratio												

Supplementary Table 2

Supplementary Table 2. Planned Sex/Gender mention in ClinicalTrial.gov by randomization				
	Not randomized, N=1134		Randomized, N=538	
	S/G Mention ¹ N=696 ²	S/G No Mention ¹ N=438 ²	S/G Mention ¹ N=336 ²	S/G No Mention ¹ N=202 ²
S/G mention in ClinicalTrial¹				
S/G mentioned ¹	58 (8.3)	-	31 (9.2)	-
Only eligibility	638 (92)	-	305 (91)	-
No mention	-	438	0 (0)	202
Study type				
Interventional	624 (90)	245 (56)	336	202
Observational / Patient Registry	72 (10)	193 (44)	0 (0)	0 (0)
Overall status				
Active, not recruiting	78 (11)	29 (6.6)	47 (14)	20 (9.9)
Completed	316 (45)	209 (48)	99 (29)	100 (50)
Recruiting/enrolling by inv	167 (24)	98 (22)	98 (29)	34 (17)
Not yet recruiting	43 (6.2)	26 (5.9)	30 (8.9)	8 (4.0)
Unknown status/Suspended	92 (13)	76 (17)	62 (18)	40 (20)
Enrollment				
≤100 ³	592 (88)	310 (72)	129 (39)	115 (57)
>100	78 (12)	123 (28)	204 (61)	86 (43)
HPV mention				
No Mention	571 (82)	374 (85)	269 (80)	174 (86)
Mention	125 (18)	64 (15)	67 (20)	28 (14)
Studies with a relevant HPV role				
Other	489 (70)	304 (69)	178 (53)	136 (67)
Oral cavity, oropharynx and larynx subsites	207 (30)	134 (31)	158 (47)	66 (33)
Phase				
Early Phase 1/Phase1	131 (21)	28 (11)	18 (5.4)	5 (2.5)
Phase 1/Phase 2	62 (9.9)	18 (7.3)	11 (3.3)	10 (5.0)
Phase 2/Phase 3	346 (55)	108 (44)	260 (77)	106 (52)
Phase 4	8 (1.3)	0 (0)	4 (1.2)	5 (2.5)
Not Applicable ³	77 (12)	91 (37)	43 (13)	76 (38)
S/G mention in published manuscripts				
S/G never described	226 (32)	91 (21)	89 (26)	45 (22)
Reported	130 (19)	59 (13)	55 (16)	37 (18)
Univariate	13 (1.9)	15 (3.4)	25 (7.4)	21 (10)
Multivariate	7 (1.0)	12 (2.7)	27 (8.0)	11 (5.4)
No publication	320 (46)	261 (60)	140 (42)	88 (44)
Randomized				
No	696	438		
Yes			336	202
¹ n (%)				

Supplementary Table 3

Supplementary Table 3. Publications on Pubmed and/or Embase related to each study registered on ClinicalTrial.gov				
Characteristic	Overall N=863 ¹	Type of mention in ClinicalTrial.gov		P-value ³
		S/G mentioned or mentioned as eligibility criteria ² N=572 ¹	S/G No mention N=291 ¹	
Type of S/G mention in the final manuscripts ²				0.01
S/G never described	451 (52%)	315 (55%)	136 (47%)	
Reported	281 (33%)	185 (32%)	96 (33%)	
Univariate	74 (8.6%)	38 (6.6%)	36 (12%)	
Multivariate	57 (6.6%)	34 (5.9%)	23 (7.9%)	
Not published	809	460	349	
¹ n (%), ² sex/gender mentioned in the analysis or as eligibility criteria, ³ Pearson's Chi-squared test				

Supplementary Table 4

Supplementary Table 4. Sex/Gender mention in protocols (only published) and S/G mention in manuscripts published					
	S/G mention	In protocol (only published)		In published paper	
Characteristic	Overall N (%)⁸⁶³¹	S/G Mention² N=572¹	S/G No mention² N=291¹	S/G Mention² N=412¹	S/G No mention² N=451¹
S/G mention in ClinicalTrial²					
S/G mentioned	36	36	0 (0)	16 (44)	20 (56)
Only eligibility	536	536	0 (0)	241 (45)	295 (55)
No mention	291	0 (0)	291	155 (53)	136 (47)
Study type					
Interventional	785	556 (71)	229 (29)	370 (47)	415 (53)
Observational / Patient Registry	78	16 (21)	62 (79)	42 (54)	36 (46)
Enrollment					
≤100 ³	592	411 (69)	181 (31)	258 (43)	334 (57)
>100	271	161 (59)	110 (41)	154 (57)	117 (43)
HPV mention					
No Mention	675	437 (65)	238 (35)	346 (51)	329 (49)
Mention	188	135 (72)	53 (28)	66 (35)	122 (65)
HPV as relevant condition					
Other	570	371 (65)	199 (35)	269 (47)	301 (53)
Oral cavity, oropharynx and larynx subsites	293	201 (69)	92 (31)	143 (49)	150 (51)
Phase					
Early Phase 1/Phase1	112	94 (84)	18 (16)	42 (38)	70 (62)
Phase 1/Phase 2	56	42 (75)	14 (25)	24 (43)	32 (57)
Phase 2/Phase 3	498	368 (74)	130 (26)	249 (50)	249 (50)
Phase 4	6	3 (50)	3 (50)	2 (33)	4 (67)
Not Applicable ³	191	65 (34)	126 (66)	95(50)	96 (50)
Randomized					
No	553	376 (68)	177 (32)	236 (43)	317 (57)
Yes	310	196 (63)	114 (37)	176 (57)	134 (43)
S/G mention in published manuscripts					
S/G never described	451	315 (70)	136 (30)	0 (0)	451
Reported	281	185 (66)	96 (34)	281	0 (0)
Univariate	74	38 (51)	36 (49)	74	0 (0)
Multivariate	57	34 (60)	23 (40)	57	0 (0)

¹ n (%), ² sex/gender mentioned in the analysis or as eligibility criteria, ³ missing values included